Abraxis BioScience, Inc. (ABII) - Financial and Strategic Analysis Review by GlobalData

VIEWS: 29 PAGES: 34

Abraxis BioScience, Inc. (Abraxis) is a biotechnology company engaged in delivering therapeutics, such as Abraxane, and core technologies. These technologies offer safe and effective treatments for cancer and other critical illnesses to patients and medical professionals. The company owns the worldwide rights to Abraxane (paclitaxel albumin), the first FDA -approved product to use the nab platform for the treatment of metastatic breast cancer. The company has its operations spread across Canada, Switzerland and other parts of the world. It has its headquarters in California, the US. Recently, the company sold its business unit and announced a new business and management structure.

Abraxis BioScience, Inc. Key Recent Developments

Jul 02, 2010 Levi & Korsinsky Investigates Possible Breach Of Fiduciary Duty By Board Of Abraxis BioSciences
May 06, 2010 Abraxis Reports Net Loss Of $3 Million For Q1 2010
Apr 19, 2010 Abraxis BioScience Updates On Overall Survival Findings From Phase I/II Study Of Nab-paclitaxel
Apr 13, 2010 SMC Accepts Abraxis BioScience Abraxane For Restricted Use Within NHS For Scotland
Mar 11, 2010 Abraxis BioScience Reports Net Loss Of $19 Million In Q4 2009

This comprehensive SWOT profile of Abraxis BioScience, Inc. provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s stren

More Info
									       Abraxis BioScience, Inc. (ABII) - Financial and Strategic Analysis Review

       Reference Code: GDME67FSA                                                                                          Publication Date: JUL 2010

       Suite 2000, 11755 Wilshire            Phone                                                      Revenue
                                                              +1 310 8831300                                               359.1 (million USD)
       Blvd.
       Los Angeles, CA                       Fax              +1 310 9988553                            Net Profit         -103.12 (million USD)
       90025                                 Website          www.abraxisbio.com                        Employees          885
       United States                         Exchange         ABII [NASDAQ]                             Industry           Medical Equipment

      Company Overview
       Abraxis BioScience, Inc. (Abraxis) is a biotechnology company engaged in delivering therapeutics, such as Abraxane, and core
       technologies. These technologies offer safe and effective treatments for cancer and other critical illnesses to patients and medical
       professionals. The company owns the worldwide rights to Abraxane (paclitaxel albumin), the first FDA -approved product to use
       the nab platform for the treatment of metastatic breast cancer. The company has its operations spread across Canada,
       Switzerland and other parts of the world. It has its headquarters in California, the US. Recently, the company sold its business
       unit and announced a new business and management structure.

      Key Executives                                                                 SWOT Analysis
                     Name                                   Title                    Abraxis BioScience, Inc., SWOT Analysis
       Bruce Wendel                         Chief Executive Officer                  Strengths                  Weaknesses

       Patrick Soon-Shiong, M.D.            Chairman
                                                                                     Focused Research and              Limited Operating Margin
       Mary Hedley                          Chief Scientific Officer                 Development Activities
       Leonard Shapiro                      Director                                                                   Limited Liquidity Position
                                                                                     Fully Integrated
       Kirk K Calhoun                       Director                                 Biotechnology Company
       Source: Annual Report, Company Website, Primary and Secondary Research
       GlobalData

      Share Data                                                                     Opportunities                     Threats
       Abraxis BioScience, Inc.
       Share Price (USD) as on 21-Jul-2010                                73.90      Drug Discovery Strategies         Product Liability and Patent
                                                                                                                       Infringement Claims
       EPS (USD)                                                          -2.57
                                                                                     Proposed Spin-Off
       Market Cap (million USD)                                           2,987                                        Emergence of
                                                                          
								
To top